Company Profile

SANOFI INDIA LTD.

NSE : SANOFIBSE : 500674ISIN CODE : INE058A01010Industry : Pharmaceuticals & DrugsHouse : Sanofi India - MNC
BSE8268.85114.2 (+1.4 % )
PREV CLOSE (Rs.) 8154.65
OPEN PRICE (Rs.) 8099.95
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 11556
TODAY'S LOW / HIGH (Rs.)8072.55 8354.00
52 WK LOW / HIGH (Rs.)5900.05 8999
NSE8269.70 125.6 (+1.54 % )
PREV CLOSE(Rs.) 8144.10
OPEN PRICE (Rs.) 8150.00
BID PRICE (QTY) 8269.70 (87 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 37451
TODAY'S LOW / HIGH(Rs.) 8090.00 8354.70
52 WK LOW / HIGH (Rs.)5900 8989

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 4.41
TTM EPS (Rs.) 207.38
P/E Ratio 39.87
Book Value (Rs.) 1215.00
Face Value (Rs.) 10
MCap (Rs. in Mn) 190436.76
Price/Earning (TTM) 34.02
Price/Sales (TTM) 6.56
Price/Book (MRQ) 6.81
PAT Margin (%) 13.49
ROCE (%) 25.75
Incorporation Year : 1956

Management Info :

Aditya Narayan - Chairman Rajaram Narayanan - Managing Director

Registered Office :

Address : Sanofi House, 117-b,L&t Business Park,Saki Vihar Road, Powai,
Mumbai,
Maharashtra-400072

Phone :

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
23Feb02-23-2021$ Appointment / Re-Appointment Of Directors, Re-Appointment Of Chairman Appointment / Re-Appointmen
The Board of Directors of the Company at its Meeting held today, based on recommendation of the Nomination and Remuneration Committee approved the appointment / re-appointment of the following Directors: 1. Re-appointment of Mr. Aditya Narayan as an Independent Director and Chairman 2. Re-appointment of Ms. Usha Thorat as an Independent Director 3. Appointment of Mr. Vaibhav Karandikar as Additional Director and Whole Time Director
The Board of Directors of the Company at its Meeting held today..
08Feb02-08-2021$Sanofi India informs about board meeting Sanofi India informs about b

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sanofi India has informed that the meeting of the Board of Directors of the Company will be held on 23rd February 2021, to approve the audited accounts for the year ended 31st December 2020 and recommend final dividend for the period mentioned above.

The above information is a part of company’s filings submitted to BSE.

Pursuant to Regulation 29 of the SEBI (Listing Obligations and..
08Feb02-08-2021$ Board Meeting Intimation for Meeting Of Board Of Directors To Be Held On 23Rd February 2021. Board Meeting Intimation fo
Sanofi India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2021 ,inter alia, to consider and approve Dear Sirs, Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company will be held on 23rd February 2021; inter alia to: Approve the audited accounts for the year ended 31st December 2020. Recommend final dividend for the period mentioned above.
Sanofi India Ltdhas informed BSE that the meeting of the Board..
08Feb02-08-2021$ Board to consider FY20 results & Final Dividend on February 23, 2021 Board to consider FY20 resu
Sanofi India Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on February 23, 2021, inter alia, to: 1. Approve the audited accounts for the year ended December 31, 2020. 2. Recommend final dividend for the period mentioned above.
Sanofi India Ltd has informed BSE that the meeting of the Board..
05Feb02-05-2021$ Proposed Divestment Of Soframycin? And Sofradex? Businesses Proposed Divestment Of Sofr
The Board of the Directors of Sanofi India Limited (the Company) at its meeting held today, reviewed the proposed plan of the Sanofi Group to globally sell some of its old brands along with their trademarks, which are owned by Sanofi Group. These include brands Soframycin? and Sofradex?, which are manufactured (through a third-party manufacturing arrangement) and distributed by the Company. The Board also noted that upon completion of such sale by Sanofi Group, the Company will not have the authority to distribute products under these brands. The business of the Company under these brands was just 2.8% of the total sales of the Company for the nine months ended 30th September 2020. The Board approved a review of options, and assessment of how best to monetise value for these businesses in India. Please take the above information on record
The Board of the Directors of Sanofi India Limited (the Company..
Financials More
Rs. in Millions
QTR Dec 20 ANNUAL 20
Net Profit12304776
Gross Profit 1702 6772
Operating Profit 18328029
Net Sales 720329019
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 14396.65 (0.34%)
M.Cap ( in Cr)
30591.88
Orchid Pharma (BSE)
 885.15 (5.00%)
M.Cap ( in Cr)
3612.86
Alembic Pharma (BSE)
 919.15 (2.38%)
M.Cap ( in Cr)
18067.10
Natural Capsules (BSE)
 117.40 (19.98%)
M.Cap ( in Cr)
73.17
Natco Pharma (BSE)
 812.60 (1.30%)
M.Cap ( in Cr)
14816.77
Shareholding Pattern More
PROMOTERS 60.4 %
FI/BANKS/INSURANCE 5.82 %
MUTUAL FUNDS/UTI 11.59 %
NON-INSTITUTION 10.62 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes